Industry pioneer InfoBionic.AI continues to push boundaries with
innovative solutions designed to improve patient outcomes and
accelerate remote cardiac telemetry advancements.
BOSTON, May 14, 2024
/PRNewswire-PRWeb/ -- InfoBionic.Ai, an innovative digital
health company providing industry-validated highest quality ECG and
AI-powered diagnostic remote patient monitoring solutions, is
pleased to announce a series of new advancements that usher in the
next generation of the MoMe ARC® product suite. "Our continued
pursuit of innovation has yielded new advancements in our MoMe ARC®
suite of products, from our next-generation MoMe ARC® 6-Lead Sensor
and upcoming MoMe ARC® 1-Lead Patch to the powerful business
intelligence of MoMe Analytics™," says Stuart Long, CEO of InfoBionic.Ai. "We are proud
to unveil a comprehensive suite of cutting-edge advancements that
will equip providers with a powerful ecosystem of solutions
designed to optimize every aspect of remote cardiac monitoring—from
patient comfort and data quality to operational efficiency and
clinical performance."
"Our continued pursuit of innovation has
yielded new advancements in our MoMe ARC® suite of products, from
our next-generation MoMe ARC® 6-Lead Sensor and upcoming MoMe ARC®
1-Lead Patch to the powerful business intelligence of MoMe
Analytics™." - Stuart Long, CEO of
InfoBionic.Ai
As the first and only continuous 6-lead FDA-cleared platform
leveraging leading-edge AI analysis and native business
intelligence, the MoMe ARC® delivers unparalleled quality,
convenience, and flexibility, empowering providers to achieve
unprecedented efficiency in diagnostic remote cardiac monitoring.
With an unwavering commitment to revolutionizing virtual cardiac
telemetry, InfoBionic.Ai continues to pioneer innovative products
that align with its mission to provide superior remote cardiac care
for all.
Introducing the Next-Generation MoMe ARC® 6-Lead Sensor
The next iteration of the MoMe ARC® 6-Lead Sensor enables providers
to obtain the highest quality in remote cardiac telemetry coupled
with the convenience of a discreetly worn wearable sensor.
The new sensor is engineered to facilitate hospital-grade virtual
cardiac telemetry, offering near real-time visibility and
AI-powered insights. Lightweight and discreet, it seamlessly
integrates into patients' existing routines, enhancing adherence
and comfort.
The latest sensor design boasts multiple configurations to
support a comprehensive range of remote cardiac monitoring needs.
With a removable and rechargeable pod, it empowers providers to
tailor the application of remote cardiac telemetry to the
individual patient's needs and allows for the physicians to choose
between multi-lead or single lead based on the patient's medical
necessity.
Coming Soon: The MoMe ARC® 1-Lead Patch
InfoBionic.Ai is in the final phase of an abbreviated submission
for the MoMe ARC® 1-Lead Patch, which will be submitted to the FDA
in early summer 2024. It will be the next addition to the MoMe ARC®
suite of patient-worn sensors. The patch release is planned to
seamlessly blend into any inventory of MoMe ARC® sensors and can be
used with or without an external cellular or Wi-Fi-based gateway,
depending on test type. The flexibility to interchange the same pod
from single to multi-lead configurations ensures that both quality
and convenience can be achieved by all.
"We are incredibly excited to forge ahead in our mission to
advance more effective remote cardiac care," says InfoBionic.Ai CEO
Stuart Long. "Our groundbreaking
upcoming MoMe ARC® 1-Lead Patch, as well as our current 6-Lead
Sensor, both embody our unwavering dedication to advancing
AI-enabled virtual cardiac telemetry and dramatically improving
patient outcomes."
Elevating Practices' Business Intelligence with MoMe
Analytics™
InfoBionic.Ai is also excited to announce the availability of MoMe
Analytics™—a business intelligence solution designed for practices
looking to take their remote cardiac monitoring business to peak
performance. MoMe Analytics™ in limited release will help practices
gain business and clinical performance never seen in remote cardiac
monitoring.
"With new insight under the categories of administrative,
clinical, technical, and financial performance, our platform allows
each practice to leverage the tremendous potential of their
patients' remote cardiac monitoring data to enable vastly improved
business decision-making and elevate cardiac care," Stuart
emphasizes. "By empowering providers to access, understand, and
utilize both practice and patient data more effectively in
combination, we enable them to unlock new levels of efficiency and
take their practice to new heights."
Meet the MoMe ARC® at HRS 2024
There's more to come for the MoMe ARC® suite of solutions.
InfoBionic.Ai will be meeting with attendees and showcasing
products at HRS 2024 in Boston
from May 16-19. Stop by booth 1267
for a live demo of these exciting new products. Visit
https://infobionic.ai/mome-arc/ to learn more about the MoMe
ARC®.
About InfoBionic.Ai
InfoBionic.Ai's digital technology has transformed the efficiency
and economics of cardiac remote patient monitoring. The company's
vision for its FDA-cleared third-generation platform, the MoMe
ARC®, is to remove the roadblocks hindering virtual and remote
diagnosis and decision-making. The Massachusetts-based team of seasoned
entrepreneurs has had successful careers in healthcare, IT, medical
devices, and mobile technology, and brings specific expertise in
remote monitoring and cardiology. Visit https://infobionic.ai.
Media Inquiries:
Karla Jo Helms
JoTo PR
727-777-5140
http://www.JoToPR.com
View original content to download
multimedia:https://www.prweb.com/releases/infobionicai-announces-next-generation-advancements-in-the-mome-arc-suite-of-products-302143127.html
SOURCE InfoBionic